Caxton Associates (UK)’s ResMed RMD Stock Holding History

Caxton Associates (UK)’s Portfolio RMD Stock Details RMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-4,225	Closed	-$1.02M	–	968
2025 Q4	$1.02M	Buy	+4,225	New	+$1.08M	0.02%	355

Other funds holding RMD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

DAM

Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Caxton Associates (UK)'s RMD Position: Q1 2026 in Review

Caxton Associates (UK) sold out of ResMed (RMD) in Q1 2026, closing a stake of 4,225 shares — an estimated $1.02M sold.

Caxton Associates (UK) first reported a position in RMD in Q4 2025 and held it in 1 quarter. The position peaked at $1.02M in Q4 2025. 938 funds tracked by Wall St. Rank hold RMD as of Q1 2026.

Caxton Associates (UK) reported no remaining ResMed position as of Q1 2026 after selling out during the quarter.
Caxton Associates (UK) sold 4,225 ResMed shares in Q1 2026, an estimated $1.02M.
Caxton Associates (UK) first reported a position in ResMed in Q4 2025 and held it in 1 quarter.
Caxton Associates (UK)'s ResMed position peaked at $1.02M in Q4 2025.
938 funds tracked by Wall St. Rank held ResMed as of Q1 2026.

Based on Caxton Associates (UK)'s 13F filing for Q1 2026, filed 14 May 2026.